Hermany Capistrano Freitas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Hermany Capistrano Freitas has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Cleonisio Leite Rodrigues
Hospital Geral de Fortaleza Fortaleza Ceará Brazil
2 shared publications - Lara Albuquerque de Brito
Hospital Geral de Fortaleza Fortaleza Ceará Brazil
2 shared publications - Alexandre Braga Libório
Medical Sciences Postgraduate Program, Universidade de Fortaleza- UNIFOR, Fortaleza, Ceará, Brazil
1 shared publication - Caio César Diniz Disserol
Universidade Federal do Paraná, Hospital de Clínicas, Curitiba PR, Brazil
1 shared publication - Eduardo Braga de Oliveira
Hospital Geral de Fortaleza, Serviço de Neurologia, Fortaleza CE, Brazil
1 shared publication - Fernanda Martins Maia Carvalho
Movement Disorders Division, Department of Neurology Hospital Geral de Fortaleza Fortaleza Brazil
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (06) , 001-005
Optimizing myasthenia gravis management in practice: integrating clinical scales and classification systems
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
- 12 May 2026
- Published by Georg Thieme Verlag KG in Arquivos de Neuro-Psiquiatria
- Vol. 84 (06) , 001-005
Open AccessOptimizing myasthenia gravis management in practice: integrating clinical scales and classification systems
Myasthenia gravis is an antibody-mediated disorder of the neuromuscular junction. Fatigability and fluctuations are hallmarks of the disease, posing a challenge: evaluation through a single physical examination may not reflect disease control. A shift towards patient-reported Outcomes is a new paradigm in the current practice, and these outcomes are usually assessed through validated scales. In the present paper, we discuss some of the most used scales in the clinical practice, such as the Myasthenia Gravis Foundation of America (MGFA) scale, the Myasthenia Gravis Activities of Daily Living (MG-ADL) scale, and the 15-Item Myasthenia Gravis Quality of Life (MG-QOL15) scale. Definitions of remission, minimal manifestation, high-burden disease, highly-active disease, and others are reviewed, and correlations involving these definitions and the scales are presented. Guidance on how to assess disease severity, therapeutic response, and a rationale for treatment escalation are explored.
- 18 December 2025
- Published by Taylor & Francis in Amyloid
- p. 1-4
Endothelial glycocalyx disruption and early renal tubular injury in hereditary transthyretin Amyloidosis with dysautonomia
- 18 December 2025
- Published by Taylor & Francis in Amyloid
- p. 1-4
Endothelial glycocalyx disruption and early renal tubular injury in hereditary transthyretin Amyloidosis with dysautonomia